CLAIMS

What is claimed is:

1. A compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof

2. The compound according to claim 1, wherein

R_1 is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, or halogen;

R_7 and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, hydroxy, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

or a pharmaceutical acceptable salt thereof.

3. The compound according to claim 2, wherein

R_1 is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, or cycloalkenyl of 4-8 carbon atoms;

R_2 is hydrogen, alkyl of 1-6 carbon atoms, halogen, or hydroxy;

R_9 is alkyl of 1-6 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_{10} is hydrogen;

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 3, wherein

R_1 is alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;

R_9 is alkyl of 1-6 carbon atoms, halogen, or trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1, which is

a) 4-(6-chloro-5-fluoro-1-methyl-1H-indazol-3-yl)phenol;

b) 4-(7-chloro-1-methyl-1H-indazol-3-yl)phenol;

c) 4-(1H-indazol-3-yl)phenol;

d) 4-(6-chloro-5-fluoro-1H-indazol-3-yl)phenol;

e) 4-(6-chloro-1H-indazol-3-yl)phenol;

f) 4-(1-butyl-1H-indazol-3-yl)phenol;

g) 4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol;

h) 4-[1-benzyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;

i) 4-(1-benzyl-7-fluoro-1H-indazol-3-yl)phenol;

j) 4-[1-benzyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;

k) 4-(1-benzyl-7-chloro-1H-indazol-3-yl)benzene-1,3-diol;

l) 4-(1-benzyl-7-fluoro-1H-indazol-3-yl)-1,3-benzenediol;

m) 4-[1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol;

n) 4-[1-(2-hydroxyethyl)-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;

o) 4-[1-methyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;

p) 4-(5-fluoro-1-methyl-1H-indazol-3-yl)phenol;

q) 4-[1-methyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;

r) 4-(7-chloro-1-methyl-1H-indazol-3-yl)benzene-1,3-diol;

s) 4-[1-methyl-5-(trifluoromethyl)-1H-indazol-3-yl]phenol;

t) 4-(5-fluoro-1-methyl-1H-indazol-3-yl)benzene-1,3-diol;

u) 4-[1-methyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol;

v) 4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol;

w) 4-[1-benzyl-5-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;

x) 4-(1-benzyl-1H-indazol-3-yl)benzene-1,3-diol;

y) 4-[7-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol;

z) 4-[5-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,3-diol;

aa) 4-[1-(2-chlorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol;

bb) 4-[6-hydroxy-1-(4-methoxyphenyl)-1H-indazol-3-yl]benzene-1,3-diol;

cc) 4-[6-hydroxy-1-(2-methoxyphenyl)-1H-indazol-3-yl]benzene-1,3-diol;

dd) 4-{6-hydroxy-1-[4-(trifluoromethoxy)phenyl]-1H-indazol-3-yl}benzene-1,3-diol;

ee) 4-[1-(3-bromophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol;

ff) 4-[1-(4-bromophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol;

gg) 4-[3-(2,4-dihydroxyphenyl)-6-hydroxy-1H-indazol-1-yl]benzonitrile;

hh) 4-[1-(3-chlorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol;

ii) 4-(1-ethyl-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol;

jj) 4-(6-hydroxy-1-propyl-1H-indazol-3-yl)benzene-1,3-diol;

kk) 4-(1-butyl-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol;

ll) 4-(1-cyclohexyl-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol;

mm) 4-[6-hydroxy-1-(2,2,2-trifluoroethyl)-1H-indazol-3-yl]benzene-1,3-diol;

nn) 4-[1-(3-fluorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol;

oo) 4-[6-hydroxy-1-(4-methylphenyl)-1H-indazol-3-yl]benzene-1,3-diol;

pp) 4-[1-(2-fluorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol;

qq) 4-[6-hydroxy-1-(3-methylphenyl)-1H-indazol-3-yl]benzene-1,3-diol;

rr) 4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol;

ss) 4-[1-(4-bromophenyl)-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;

tt) 4-[1-cyclohexyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;

uu) 4-(7-methyl-1H-indazol-3-yl)phenol;

vv) 4-[1-(3-chloro-4-fluorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol;

ww) 4-{6-hydroxy-1-[3-(trifluoromethyl)phenyl]-1H-indazol-3-yl}benzene-1,3-diol;

xx) 4-[6-hydroxy-1-(3-nitrophenyl)-1H-indazol-3-yl]benzene-1,3-diol;

yy) 4-[6-hydroxy-1-(4-isopropylphenyl)-1H-indazol-3-yl]benzene-1,3-diol;
zz) 4-{6-hydroxy-1-[4-(methylsulfonyl)phenyl]-1H-indazol-3-yl}benzene-1,3-diol;
aaa) 4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol;
bbb) 4-(1-isopropyl-7-methyl-1H-indazol-3-yl)phenol;
ccc) 4-(7-chloro-1-pentyl-1H-indazol-3-yl)phenol;
ddd) 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol;
eee) 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)phenol;
fff) 4-[1-pentyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;
ggg) 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;
hhh) 4-[1-propyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;
iii) 4-(7-methyl-2-propyl-2H-indazol-3-yl)phenol;
jjj) 4-[2-isopropyl-7-methyl-2H-indazol-3-yl]phenol;
kkk) 4-(7-chloro-2-pentyl-2H-indazol-3-yl)phenol;
lll) 4-(7-chloro-2-propyl-2H-indazol-3-yl)phenol;
mmm) 4-(7-chloro-2-isopropyl-2H-indazol-3-yl)phenol;
nnn) 4-[1-butyl-6-(trifluoromethyl)-1H-indazol-3-yl]phenol;
ooo) 4-(1-butyl-6-chloro-1H-indazol-3-yl)phenol;
ppp) 4-(7-fluoro-1-methyl-1H-indazol-3-yl)phenol;
qqq) 4-(1H-indazol-3-yl)benzene-1,2-diol;
rrr) 4-(7-fluoro-1H-indazol-3-yl)phenol;
sss) 4-[1-butyl-5-(trifluoromethyl)-1H-indazol-3-yl]phenol;
ttt) 4-(1-cyclohexyl-7-fluoro-1H-indazol-3-yl)phenol;
uuu) 4-(1-allyl-7-fluoro-1H-indazol-3-yl)phenol;
vvv) 4-(1-allyl-7-methyl-1H-indazol-3-yl)phenol;
www) 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;
xxx) 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol;
yyy) 4-(7-fluoro-1-propyl-1H-indazol-3-yl)phenol;
zzz) 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)phenol;
aaaa) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol;
bbbb) 4-[1-butyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;
cccc) 4-(1-butyl-7-fluoro-1H-indazol-3-yl)phenol;
dddd) 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]phenol;
eeee) 4-(7-chloro-2-cyclopentyl-2H-indazol-3-yl)phenol;

ffff) 4-(2-cyclopentyl-7-fluoro-2H-indazol-3-yl)phenol;

gggg) 4-(7-fluoro-2-isopropyl-2H-indazol-3-yl)phenol;

hhhh) 4-(7-fluoro-2-propyl-2H-indazol-3-yl)phenol;

iiii) 4-[7-fluoro-1-(3,3,3-trifluoropropyl)-1H-indazol-3-yl)phenol;

jjjj) 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]-3-methylphenol;

kkkk) 3-methyl-4-[1-propyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;

llll) 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;

mmmm) 4-[1-pentyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;

nnnn) 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]-3-methylphenol;

oooo) 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]-1,3-benzenediol;

pppp) 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)-3-methylphenol;

qqqq) 4-(7-chloro-2-isopropyl-2H-indazol-3-yl)-3-methylphenol;

rrrr) 4-(7-chloro-1-propyl-1H-indazol-3-yl)-3-methylphenol;

ssss) 4-(7-chloro-2-propyl-2H-indazol-3-yl)-3-methylphenol;

tttt) 4-(1-allyl-7-chloro-1H-indazol-3-yl)-3-methylphenol;

uuuu) 4-(2-allyl-7-chloro-2H-indazol-3-yl)-3-methylphenol;

vvvv) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)-2-methylphenol;

wwww) 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)-3-methylphenol;

xxxx) 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)benzene-1,3-diol;

yyyy) 4-(1-allyl-7-chloro-1H-indazol-3-yl)benzene-1,3-diol;

zzzz) 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]-3-methylphenol;

aaaaa) 4-(1-isopropyl-7-thien-3-yl-1H-indazol-3-yl)phenol;

bbbbb) 4-(1-isopropyl-7-thien-2-yl-1H-indazol-3-yl)phenol;

ccccc) 4-{1-isopropyl-7-[4-(methylthio)phenyl]-1H-indazol-3-yl}phenol;

ddddd) 4-{7-[4-(hydroxymethyl)phenyl]-1-isopropyl-1H-indazol-3-yl}phenol;

eeeee) 4-[3-(4-hydroxyphenyl)-1-isopropyl-1H-indazol-7-yl]benzene-1,2-diol;

fffff) 4-[7-(4-ethylphenyl)-1-isopropyl-1H-indazol-3-yl]phenol;

ggggg) 4-[7-(1,1'-biphenyl-4-yl)-1-isopropyl-1H-indazol-3-yl]phenol;

hhhhh) 4-[7-(2-chlorophenyl)-1-isopropyl-1H-indazol-3-yl]phenol;

iiiii) 4-[1-isopropyl-7-(2-methylphenyl)-1H-indazol-3-yl]phenol;

jjjjj) 4-(1-isopropyl-7-phenyl-1H-indazol-3-yl)phenol;

kkkkk) 4-{1-cyclopentyl-7-[4-(trifluoromethyl)phenyl]-1H-indazol-3-yl}phenol;

lllll) 4-(1-cyclopentyl-7-thien-2-yl-1H-indazol-3-yl)phenol;

mmmmm) 4-[1-cyclopentyl-3-(4-hydroxyphenyl)-1H-indazol-7-yl]benzene-1,2-diol;

nnnnn) 4-[1-cyclopentyl-7-(4-ethylphenyl)-1H-indazol-3-yl]phenol;

ooooo) 4-[7-(2-chlorophenyl)-1-cyclopentyl-1H-indazol-3-yl]phenol;

ppppp) 4-[1-cyclopentyl-7-(2-furyl)-1H-indazol-3-yl]phenol;

qqqqq) 4-[1-cyclopentyl-7-(2-methylphenyl)-1H-indazol-3-yl]phenol;

rrrrr) 4-(1-cyclopentyl-7-phenyl-1H-indazol-3-yl)phenol;

sssss) 4-(1-isopropyl-7-thien-3-yl-1H-indazol-3-yl)-3-methylphenol;

ttttt) 4-{7-[(1E)-hept-1-enyl]-1-isopropyl-1H-indazol-3-yl}-3-methylphenol;

uuuuu) 4-{7-[4-(hydroxymethyl)phenyl]-1-isopropyl-1H-indazol-3-yl}-3-methylphenol;

vvvvv) 4-[3-(4-hydroxy-2-methylphenyl)-1-isopropyl-1H-indazol-7-yl]benzene-1,2-diol;

wwwww) 4-[7-(4-ethylphenyl)-1-isopropyl-1H-indazol-3-yl]-3-methylphenol;

xxxxx) 4-[7-(1,1'-biphenyl-4-yl)-1-isopropyl-1H-indazol-3-yl]-3-methylphenol;

yyyyy) 4-[7-(2-chlorophenyl)-1-isopropyl-1H-indazol-3-yl]-3-methylphenol;

zzzzz) 4-[7-(2-furyl)-1-isopropyl-1H-indazol-3-yl]-3-methylphenol;

aaaaaa) 4-[1-isopropyl-7-(2-methylphenyl)-1H-indazol-3-yl]-3-methylphenol;

bbbbbb) 4-(1-isopropyl-7-phenyl-1H-indazol-3-yl)-3-methylphenol;

cccccc) 4-{1-cyclopentyl-7-[4-(methylthio)phenyl]-1H-indazol-3-yl}-3-methylphenol;

dddddd) 4-{1-cyclopentyl-7-[(1E)-hept-1-enyl]-1H-indazol-3-yl}-3-methylphenol;

eeeeee) 4-[1-cyclopentyl-3-(4-hydroxy-2-methylphenyl)-1H-indazol-7-yl]benzene-1,2-diol;

ffffff) 4-[1-cyclopentyl-7-(4-ethylphenyl)-1H-indazol-3-yl]-3-methylphenol;

ggggggg) 4-[7-(1,1'-biphenyl-4-yl)-1-cyclopentyl-1H-indazol-3-yl]-3-methylphenol;

hhhhhh) 4-[7-(2-chlorophenyl)-1-cyclopentyl-1H-indazol-3-yl]-3-methylphenol;

iiiiii) 4-[1-cyclopentyl-7-(2-furyl)-1H-indazol-3-yl]-3-methylphenol;

jjjjjj) 4-[1-cyclopentyl-7-(2-methylphenyl)-1H-indazol-3-yl]-3-methylphenol;

kkkkkk) 4-(1-cyclopentyl-7-phenyl-1H-indazol-3-yl)-3-methylphenol;

llllll) 4-[7-(1-benzothien-2-yl)-1-cyclopentyl-1H-indazol-3-yl]-3-methylphenol;

mmmmmm) 4-[7-(2-furyl)-1-isopropyl-1H-indazol-3-yl]phenol;

nnnnnn) 4-(7-fluoro-1-propyl-1H-indazol-3-yl)-3-methylphenol;
oooooo) 4-(7-fluoro-2-propyl-2H-indazol-3-yl)-3-methylphenol;
pppppp) 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)-3-methylphenol;
qqqqqq) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)benzene-1,3-diol;
rrrrrr) 4-(7-fluoro-1-isobutyl-1H-indazol-3-yl)-3-methylphenol;
ssssss) 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)benzene-1,3-diol;
tttttt) 4-(7-fluoro-2-isopropyl-2H-indazol-3-yl)benzene-1,3-diol;
uuuuuu) 4-(7-fluoro-1-isobutyl-1H-indazol-3-yl)benzene-1,3-diol;
vvvvvv) 4-[3-(4-hydroxyphenyl)-1-propyl-1H-indazol-7-yl]phenol;
wwwwww) 4-[7-(4-fluorophenyl)-1-propyl-1H-indazol-3-yl]phenol;
xxxxxx) 4-(7-morpholin-4-yl-1-propyl-1H-indazol-3-yl)phenol;
yyyyyy) 4-(7-phenyl-2-propyl-2H-indazol-3-yl)phenol;
zzzzzz) 4-(7-phenyl-1-propyl-1H-indazol-3-yl)phenol;
aaaaaaa) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl pivalate;
bbbbbbb) 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenyl 3,3-dimethylbutanoate;
ccccccc) 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenyl propionate;
ddddddd) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl acetate;
eeeeeee) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl propionate;
fffffff) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl N-(tert-butoxycarbonyl)glycylglycinate;
ggggggg) 1-tert-butyl 5-[4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl] N-(tert-butoxycarbonyl)-L-glutamate;
hhhhhhh) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl ethylcarbamate;
iiiiiii) 4-(7-chloro-1-thien-3-yl-1H-indazol-3-yl)phenol;
jjjjjjj) 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;
kkkkkkk) methyl 3-(4-hydroxyphenyl)-2-isopropyl-2H-indazole-7-carboxylate;
lllllll) 4-[1-cyclopentyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;
mmmmmmm) 4-[1-(cyclohexylmethyl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;
nnnnnnn) 4-[1-isobutyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;
ooooooo) 4-[1-cyclobutyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;
ppppppp) 4-[1-(2-ethylbutyl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol,

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition, which comprises a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of

6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. A method of treating or inhibiting chronic inflammatory disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

8. A method of treating or inhibiting rheumatoid arthritis, spondyloarthropathies, osteoarthritis, psoriatic arthritis, or juvenile arthritis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of

6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

9. A method of treating or inhibiting inflammatory bowel disease, Crohn's disease, ulcerative colitis, or indeterminate colitis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

10 A method of treating or inhibiting psoriasis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon

atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

11. A method of treating or inhibiting asthma or chronic obstructive pulmonary disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

12. A method of treating or inhibiting stroke, ischemia, or reperfusion injury in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

13. A method of lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, acute coronary syndrome, peripheral vascular disease, restenosis, or vasospasm in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

14. A method of treating or inhibiting Alzheimer's disease, cognitive decline, or senile dementia in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

15. A method of treating or inhibiting type II diabetes in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially

unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

16. A method of treating or inhibiting sepsis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.